1nhaler
$1.9M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
1nhaler is currently valued at $13.8M as of November 17, 2025. The company has raised a total of $4.5M in funding.
Capital Efficiency
With a capital efficiency ratio of 3.05x, 1nhaler has achieved a valuation that is 3.05 times the total capital raised. This metric indicates strong capital efficiency and effective deployment of investor funds.
Investment Perspective
1nhaler's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is 1nhaler Worth in 2025?
As of 2025, 1nhaler is valued at $13.8M, based on the company's Later Stage VC funding round in November 17, 2025. This valuation positions 1nhaler as one of the leading private companies in the sector.
1nhaler Valuation History
1nhaler's funding history demonstrates steady growth and investor confidence.
How 1nhaler Valuation is Determined
Private company valuations like 1nhaler's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
1nhaler Valuation FAQs
Is 1nhaler profitable?
1nhaler has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does 1nhaler's valuation compare to competitors?
1nhaler is valued at $13.8M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will 1nhaler IPO?
1nhaler has not announced plans for an initial public offering. Until an IPO, investors can access 1nhaler shares through secondary market platforms.